Clinical trials: Lymphopenia
Idiopathic CD4 Lymphopenia
A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
Background: Idiopathic CD4 lymphopenia (ICL) is a syndrome characterized by low levels of certain immune cells called CD4 T cells.
- Trial name
- NCT05600920
- Testing
- Recombinant human interleukin (IL) 7-hyFc
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Corona Virus Infection
Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia
This is a phase I/II clinical trial using adoptive cell therapy with NK cells or memory T cells in patients affected by COVID-19.
- Trial name
- RELEASE (NCT04578210)
- Testing
- T memory cells and NK cells
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Solid Cancer, Lymphopenia
Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors
The goal of this clinical trial is to evaluate the effectiveness of PRaG-1 in improving CD8+ lymphocytopenia in patients with solid tumors who are tumor-free for more than six months after completing radiotherapy and/or…
- Trial name
- NCT07258160
- Testing
- PRaG-1
- Where
- China
- Volunteers
- 127 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Cardiopulmonary Bypass
Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor
In previous studies, 90% of patients who underwent elective cardiopulmonary bypass procedure manifested CD4 counts of less than 500 cells/microliter in the immediate (day 1) post-operative period.
- Trial name
- NCT00385450
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
THC, Cannabis
THC Crossover Study
This is a randomized, crossover study enrolling experienced dual cannabis-tobacco smokers (N=18) to describe the differences in THC and toxicant exposure, examining pharmacokinetic, subjective, and cardiovascular effects from…
- Conditions
- THC, Cannabis, Cannabis Smoking, Cannabis Use, Unspecified
- Trial name
- TRDRP (NCT04429568)
- Testing
- Smoked Cannabis, Vaped Cannabis, Tobacco Cigarette
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- PRO-RIC (NCT04528355)
- Testing
- data collection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Paul Szabolcs
HIV-1-infection, CD4+ T Lymphocytopenia
Pyridostigmine as Immunomodulator in People Living With HIV
Human immunodeficiency virus (HIV) infection is characterized by persistent immune activation and a constant turnover of T cells. This leads to a precipitous fall in the number of T cells, as well as to an early immunosenescence.
- Conditions
- HIV-1-infection, CD4+ T Lymphocytopenia, Immune Deficiency, Immuno-senescence
- Trial name
- NCT03312244
- Testing
- Pyridostigmine Bromide
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS)
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
This is a Phase 3, randomized, blinded, and placebo-controlled clinical trial investigating a new combination treatment for critically ill adults who have severe community-acquired pneumonia, especially if they also have sepsis…
- Conditions
- Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia
- Trial name
- NCT07492875
- Testing
- Nogapendekin alfa inbakicept (NAI), agenT-797
- Sponsor
- ImmunityBio, Inc.
Lymphopenia
Persistent Lymphopenia in Liver Transplantation and Its Molecular Insights for Hepatocellular Carcinoma
A total of 145 Liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) were retrospectively enrolled at Kaohsiung Chang Gung Memorial Hospital between 2006 and 2019.
- Trial name
- NCT06368349
- Where
- Taiwan
- Volunteers
- 190 people
- Sponsor
- Chang Gung Memorial Hospital
Wiskott-Aldrich Syndrome
Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome
The Wiskott-Aldrich Syndrome (WAS) is an inherited disorder that results in defects of the blood and bone marrow. It affects boys because the genetic mistake is carried on the X chromosome.
- Trial name
- NCT01410825
- Testing
- Retrovirus-mediated gene transfer
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- David Williams
Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
OBJECTIVES: I. Provide curative immunoreconstituting allogeneic bone marrow transplantation for patients with primary immunodeficiencies. II.
- Conditions
- Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease
- Trial name
- NCT00006054
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Fairview University Medical Center
COVID-19, Lymphocytopenia
InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort
Comparison of the effects of CYT107 vs Placebo administered IM at 10µg/kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.
- Trial name
- ILIAD-7-UK (NCT04379076)
- Testing
- Interleukin-7
- Where
- 13 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Revimmune
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/ kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.
- Trial name
- ILIAD-7-FR (NCT04407689)
- Testing
- Interleukin-7
- Where
- 6 sites in France
- Volunteers
- 34 people
- Sponsor
- Revimmune
Cancer of the Digestive System, Thoracic Diseases
Assessment of Postoperative Lymphopenia as Risk Factor for Postoperative Infections
Postoperative infections are one of the most common complications in thoracic and digestive cancer surgery. Former studies have demonstrated that inflammatory response is altered during peri-operative period causing lymphopenia.
- Trial name
- EVALYMPH (NCT02799251)
- Testing
- Collection of plasma cell rate
- Where
- 20 sites in France
- Volunteers
- 1,125 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Immunology of Septic Shock
Evaluation of Immunosuppression in Septic Shock: Biomarkers and Pharmacological Restoration (IMMUNOSEPSIS)
Septic syndromes (systemic inflammatory response associated with infection) remain a major although largely under-recognized health care problem and represent the first cause of mortality in intensive care units.
- Trial name
- IMMUNOSEPSIS (NCT02803346)
- Testing
- Circulating blood (leukocytes)
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Hospices Civils de Lyon
Malignant Neoplasms of Brain
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells.
- Trial name
- ATTAC (NCT00639639)
- Testing
- tetanus toxoid, therapeutic autologous dendritic cells, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Gary Archer Ph.D.
Sepsis, Severe
Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients
This phase II randomized study will assess the effect of receiving IV recombinant human IL-7 (CYT107) versus placebo in lymphopenic sepsis patients The aim is to confirm the immune cell reconstitution observed in other studies…
- Trial name
- IRIS-7-C&D (NCT03821038)
- Testing
- CYT107
- Where
- 10 sites in United States, France
- Volunteers
- 21 people
- Sponsor
- Revimmune
Wiskott-Aldrich Syndrome (WAS), X-linked Thrombocytopenia
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome
Funding Source--FDA OOPD. Orphan Product Grant Number--1R01FD004091-01A1 Context: Wiskott-Aldrich syndrome (WAS) is a fatal, devastating disease with ill-defined treatment modalities, which affects young boys.
- Trial name
- WAS (NCT00774358)
- Testing
- Interleukin-2
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Soma Jyonouchi